Radiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics announced dosing of the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 (177Lu-Betabart) at 70 mCi, following a positive recommendation from the Safety and Monitoring Committee. RV-01 is a 177Lutetium-tagged monoclonal antibody targeting B7-H3 in patients with B7-H3 expressing solid tumors, developed through a joint venture with MD Anderson Cancer Center.

Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 34.6% to $4.32 during Monday's pre-market session. The company's market cap stands at $6.5 million. As per the press release, Q2 earnings came out 3

Radiopharm Theranostics Says Data Safety And Monitoring Committee Recommends Advancing RAD202 To 180mCi Dose Level In Phase 1 HEAT Trial In HER2-Positive Advanced Solid Tumors